Everywhere IDO

Incyte Corp. and partner Merck & Co. Inc. now have reported the data that led them to plan Phase III trials that combine their molecules in five cancer indications. For Incyte, the next step is looking for how it might extend the benefits of its epacadostat IDO1 inhibitor into tumor types where the doublet with the pharma’s Keytruda anti-PD-1 mAb wasn’t enough.

That could mean adding a third mechanism to the doublet, as well as other combinations within Incyte’s own pipeline that will be guided by preclinical and clinical investigations of tumor immune biology...